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Abstract introduction There are concerns that immediate ART initiation (regardless of CD4 count)
negatively affects HIV status disclosure, ART adherence and healthcare interactions. We assessed
changes in these factors after the ‘Early access to ART for all’ intervention, a universal test-and-treat
study in Swaziland.
methods We recruited two samples of participants between 2014 and 2017. The first group was
interviewed before the intervention (control); the second group at the implementation and 6 months
thereafter (intervention).
results High levels of disclosure to partners (controls and intervention: 94%) and family members
(controls: 78%, intervention: 79%) were reported, and high levels of adherence (85% did not miss a
dose among the controls, 84% in the intervention group). There were no changes in patients
reporting feeling pressured to initiate ART (controls: 10%, intervention: 11%). The quality of
interaction with healthcare workers improved after the intervention; healthcare workers explained
more often the choice of ART initiation (controls: 88%, intervention: 93%) and the meaning of both
CD4 and viral load test results (controls: 15%, intervention: 47%). More patients in the intervention
group reported receiving test results (controls: 13%, intervention: 46%). We observed no changes in
disclosure, adherence or patient experiences 6 months into the intervention compared to its start.
conclusion Our results suggest that both reported adherence and disclosure levels remain high
after the introduction of immediate ART in Swaziland. We observed an improvement in the
healthcare interactions, possibly due to training at participating facilities, which will be an important
element for a successful roll-out of immediate ART.
keywords HIV, antiretroviral therapy, disclosure, adherence, treatment as prevention, Swaziland
Introduction
International recommendations on the initiation of
antiretroviral therapy (ART) included a threshold based on
the patient’s CD4 count until 2015 [1–3], when WHO rec-
ommended initiation of ART on positive HIV diagnosis,
regardless of WHO clinical stage or CD4 count [4].
Concerns have been raised that early initiation of ART
might be associated with lower levels of treatment
adherence. These concerns are based on studies where
more treatment interruptions and an increased risk of loss
to follow-up was observed in people who started ART at
a higher baseline CD4 count [5, 6]. People with higher
CD4 count were less likely to start ART when offered,
primarily because they reported feeling healthy [7, 8].
However, a study in Uganda challenged these concerns
and found that individuals starting ART with a higher
baseline CD4 cell count were equally adherent as those
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starting with lower CD4 counts [8]. A systematic review
did not find evidence to conclude that baseline CD4
count has an effect on ART adherence [9]. Qualitative
research identified barriers to starting ART regardless of
CD4 count, such as feeling healthy, fear of side effects
and stigma [10, 11]. In particular, early initiation of ART
also entails a fear of unintended disclosure, from visible
side-effects or being seen accessing HIV services [10].
Factors that positively impact ART adherence are, among
others, increased levels of disclosure of HIV status [12–
14], better communication with healthcare workers [13],
and reduced HIV-related stigma [15], which is expected
to decrease after an increased ART coverage [16].
Swaziland (statutory name of the country at time of
study, current statutory name is Eswatini) is a country
with a high HIV prevalence with 27% of adults HIV pos-
itive in 2016 [17]. Based on international guidelines, the
Swaziland National AIDS Program (SNAP) has changed
national recommendations from an initiation threshold of
CD4 count < 200 cells/mm3 in 2003 to < 500 cells/mm3
in 2015 and to universal test and treat in October 2016
[18, 19]. ART coverage among diagnosed HIV positive
adults was 87% in 2016 [17].
The consortium Maximising antiretroviral therapy for
better health and zero new infections (MaxART) imple-
mented an ‘Early access to ART for all’ intervention in
selected public facilities in Hhohho region, Swaziland.
This meant that all HIV positive adults received ART,
regardless of WHO clinical stage and CD4 count [18].
The objective of this study was to assess whether the
implementation of an ‘Early access to ART for all’ inter-
vention changed patterns of disclosure, treatment adher-
ence and healthcare interactions. We hypothesised that
(1) starting ART early could have an effect on disclosure.
The effect could be an increase in disclosure as patients
starting ART early would benefit from reduced transmis-
sion and therefore treatment could be seen as a protec-
tion against transmission. However, patients starting
early ART may be less likely to disclose due to the lack
of symptoms, and therefore a reduced need to do so
while avoiding HIV-related stigma; and (2) patients start-
ing ART early are less likely to adhere to treatment com-
pared to patients initiating ART as per standard of care,
because they might feel healthier.
Methods
Setting
The MaxART study is a multidisciplinary implementation
study in Hhohho Region, Swaziland assessing the impact
of ‘Early Access to ART for All’ (EAAA) using clinical,
social science and economic outcomes. This study is a
social science sub-study of the MaxART implementation
study [18]. The MaxART study protocol is described in
detail elsewhere [18]. Briefly, the MaxART study imple-
mented an EAAA intervention for all HIV positive, ART
na€ıve individuals attending one of the participating facili-
ties. The study used a stepped-wedge design, where facili-
ties transitioned from control (national ART guidelines)
to intervention (EAAA). The MaxART study took place
in 14 facilities, whereas this sub-study used nine of those,
purposefully selected to include larger and smaller facili-
ties and based on previous research in these facilities
[19].
Participants
For this study we conducted interviews at three time
points with MaxART study participants, one before the
intervention and two during. The control group, inter-
viewed at the first time point, consisted of a random sam-
ple of HIV-positive patients who initiated ART less than
12 months prior to the interview in a facility included in
the MaxART study, where the intervention was not yet
implemented (i.e. these patients were treated following
the national ART guidelines, with an ART initiation
threshold of 350 cells/mm3). The intervention group was
interviewed at two time points. At the first time point
during the intervention (t0), the group consisted of
patients recruited randomly after the facility had been
implementing the EAAA strategy for at least 3 months.
Patients were eligible for interviews if they had a CD4
count above 350, WHO clinical stage 1 or 2 and were
willing to be contacted 6 months later for a follow-up
interview. These respondents were interviewed at a sec-
ond time point during the intervention, which composed
the intervention t1 group.
Sample size
We calculated a required sample size of 380 HIV positive
patients per survey round to be able to detect a 5%
change in prevalence of disclosure or self-reported adher-
ence between two interview rounds, with a power of
90% and a significance level of 0.05, accounting for a
design effect of 1.5 due to clustering of the data, caused
by recruitment in clinics.
Data collection
Trained Swazi research assistants collected data using a
semi-structured questionnaire in siSwati. The question-
naire was adopted from the WHO’s manual HIV Testing,
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Treatment and Prevention: Generic Tools for Operational
Research [20] and translated into siSwati by two native
siSwati speakers. The questionnaire was pre-tested before
finalisation. The questionnaire included both close and
open-ended questions and was administered face-to-face.
Respondents’ answers were entered in siSwati on the
paper-based questionnaire by the research assistants.
Data collection for the control group took place from
September 2014 to September 2015. For the intervention
t0 group, data collection took place from April 2015 to
June 2017. The follow-up (t1), took place from January
2016 to May 2017.
Data were entered in Excel. The open-ended answers
were entered in siSwati, and translated into English by
the research assistant who carried out the interview. Data
entry and translation was cross-checked by a second
research assistant, and any inconsistencies were discussed
and checked by a third member of the team before the
database was finalised. Records were anonymised and
labelled as control, intervention t0 and intervention t1.
We linked records between intervention t0 and t1 after
three approaches: (i) on study identifier (68%); when that
was not available (ii) on local identifier (25%); when that
was not available (iii) on an algorithm that took into
account gender, birth year, religion, facility, education
and marital status (7%). In the follow-up round (t1), 19
questionnaires could not be matched using any of the
three criteria and are therefore not included in the final
analysis.
Data analysis
We obtained socio-demographic information as well as
information on the primary outcomes disclosure and
adherence, and the secondary outcomes of healthcare
interactions. Disclosure was assessed via questions on
keeping HIV status a secret, with whom the respondent
shared their HIV status, and whether their HIV status
has been disclosed as a consequence of visiting healthcare
services or taking ART. Adherence was a self-reported
measure assessing if the respondent missed a dose of
ART in the last 30 days. For patient experiences of HIV-
testing, the respondents were asked if they felt ill when
they went for HIV testing. For patient experiences of
ART initiation, they were asked if they felt ill (generally
unwell) when initiating ART, if they felt pressured to
start ART, and what the main reason was to start ART
as an open-ended question. Healthcare interaction was
assessed by asking respondents what the healthcare work-
ers usually asked, explained and reported, both at start
of ART and at refill visits. Age was calculated based on
reported birth and interview dates. Education was
categorised into no formal education, primary, secondary,
higher and other. Marital status was categorised into
married, not married but in a relationship and not in a
relationship. Religion was categorised into mainstream
Christian, Evangelical (born-again churches), African
Healing Churches, other and none. The categorisation for
religion and marital status was decided upon in consulta-
tion with anthropologists in the study team who were
familiar with the local context. The wealth index was
created based on a principal component analysis of eight
variables assessing the presence of household assets. The
resulting wealth score was used to divide the respondents
in the control group in wealth quintiles. The cut-off val-
ues of the quintiles in the control group were used to
divide the respondents in the intervention t0 and t1 group
into five groups based on their wealth score. The answers
from the open-ended question were classified in themes
and the most reported are cited. Frequencies are com-
pared using Pearson’s chi squared test and Fisher’s exact
test, where appropriate. We did not take into account
clustering of participants in the health facilities, given the
emphasis on frequencies rather than effect size. For com-
parisons between before and during intervention on an
aggregated level, we used the control and intervention t0
group, for comparisons over time during the intervention
on patient level, we used the intervention t0 and t1, but
only including the respondents who were followed up.
We used Stata 14.2 for all analyses. The two-sided
a-value was set at 0.05.
Ethical review
The MaxART implementation study and this social
science sub-study were approved by the Swaziland
National Health Research Review Board in July 2014
(Reference Number: MH/599C/FWA 000 15267). Indi-
viduals were included in the MaxART study after giving
informed oral consent and they provided additional writ-
ten consent to be interviewed for this sub-study.
Results
The recruitment of participants in the control and inter-
vention group is described in Figure 1. In the control
group we achieved the planned sample size, however, in
the intervention group we achieved only 63% of the
planned sample size, due to delays in recruitment. The
participants’ characteristics are described in Table 1. The
majority of the sample was female. The mean age was
slightly higher in the intervention group (38 years) com-
pared with the control group (35 years). Most partici-
pants had either no education or finished only primary
© 2019 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 565
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education. The socio-economic distribution was skewed
towards the lower groups in the intervention groups com-
pared with the control (24.4% in the poorest group in
the controls vs. 31.3% in the intervention group).
Comparing disclosure before and during the interven-
tion, a high proportion of participants (94%) reported to
have disclosed their HIV status to their partner at both
time points (Table 2). Disclosure to family showed simi-
lar proportions in control and intervention group (78%
in the control group and 79% in the intervention t0
group). Disclosure outside the family was rare, indepen-
dently of the timing of ART initiation. The disclosure
patterns did not change over time during the interven-
tion. The proportion of people worried about non-
intended disclosure after visits to healthcare services or
taking ART differed between control (14%) and interven-
tion group (20%).
Reported treatment adherence did not change with the
introduction of early ART, nor over time during the
intervention. However, of those that felt ill when starting
ART, 20.0% (34/170) reported missing a dose, whereas
of those that did not feel ill 12.5% (58/431) reported
missing a dose (P = 0.045).
The proportion of respondents feeling ill when testing
was higher in the control group (36.4%) than in the
intervention t0 group (28.1%) (Table 2). The proportion
of respondents feeling ill when initiating ART was higher
in the control group (32.5%) compared to the interven-
tion group (21.5%).
An increased proportion of respondents was told that it
was their own choice to start ART, and both the CD4
count and the viral load test were explained more often in
the intervention (from 64.6% in t0 to 75.0% in t1 for the
CD4 count and from 19.2% in t0 to 52.6% in t1 for the
viral load test) compared to the control group (Table 3).
At ART refill, the introduction of the intervention was
associated with a significant increase in participants who
reported that they were given the CD4 count and viral load
test results, namely from 14.0% to 48.9% for viral load
test results and from 68.8% to 76.3% for CD4 count
results. Over time during the intervention, the number of
participants reporting that they received the CD4 count
and viral load test results increased, from 44.2% to 67.0%
for viral load, and from 75.5% to 84.5% for CD4 count
results. There was no change in the proportion of respon-
dents feeling pressured to start ART.
Control
Approched: 401
Refused to participate, n = 32
369 interviews
Control: 369 patients included T0: 233 patients included T1: 116 patients included
Interviewed in T0 and T1:
97 patients included
T0: 239 interviews
Excluded, n = 6
Excluded, n = 2
Protocol violations, n = 4
Refused to participate, n = 3
Not followed up, n = 121
Protocol violations, n = 2
Not able to link to T0, n = 19
T1: 118 interviews at follow up
Intervention T0
Approached: 242
Duplicates, n = 2
Figure 1 Recruitment flowchart.
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Discussion
We found no changes in patterns of disclosure and treat-
ment adherence after the EAAA intervention, with both
being reported by a very high percentage of patients at
each of the interview rounds. Respondents did not report
more pressure to start ART after the intervention was
introduced, indicating that, even though all HIV-positive
individuals were eligible to start ART, initiation remained
a choice.
The literature reports mixed results from studies on
treatment adherence in patients starting ART at higher
baseline CD4 count, yet our results are in line with the
study by Jain et al. [8] that challenged the concerns on
treatment adherence in this patient group, as reported by
Adakun et al. [5]. It should be noted that this latter study
took place before the WHO guideline changed. We found
that more people worried that visiting HIV testing and
counselling (HTC) services or taking ART may disclose
their HIV status after the intervention, which is in line with
a qualitative study in Kenya that cited fear of unintended
disclosure as a barrier to early initiation of ART [10].
Feeling healthy was reported as a reason for delayed
ART initiation in a qualitative sub-study carried out in
Table 1 Characteristics of study participants
Control Intervention t0
Intervention t0
(who are followed up)
n/N (%) n/N (%) n/N (%)
N 369 (100) 233 (100) 97 (100)
Age: mean (SD) 35 (10.5) 38 (11.8) 39 (10.8)
Sex: female 282/369 (76.4) 182/233 (78.1) 74/97 (76.3)
Education
No formal education 51/369 (13.8) 49/233 (21.0) 19/97 (19.6)
Primary 133/369 (36.0) 76/233 (32.6) 29/97 (29.9)
Secondary 102/369 (27.6) 73/233 (31.3) 31/97 (32.0)
Higher 76/369 (20.6) 32/233 (13.7) 17/97 (17.5)
Other 7/369 (1.9) 3/233 (1.3) 1/97 (1.0)
Marital status
Married 212/369 (57.5) 127/232 (54.7) 54/96 (56.3)
Relationship, not married 117/369 (31.7) 63/232 (27.2) 26/96 (27.1)
Not in a relationship 40/369 (10.8) 42/232 (18.1) 16/96 (16.7)
Religion
Evangelical 110/369 (29.8) 74/233 (31.8) 34/97 (35.1)
Mainstream Christian 21/369 (5.7) 12/233 (5.2) 3/97 (3.1)
African Healing Churches 196/369 (53.1) 125/233 (53.7) 52/97 (53.6)
Other 5/369 (1.4) 2/233 (0.9) 0
None 37/369 (10.0) 20/233 (8.6) 8/97 (8.3)
Wealth index
Poorest 90/369 (24.4) 73/233 (31.3) 28/97 (28.9)
Poor 59/369 (16.0) 24/233 (10.3) 10/97 (10.3)
Middle 73/369 (19.8) 32/233 (13.7) 15/97 (15.5)
Rich 78/369 (21.1) 64/233 (27.5) 33/97 (34.0)
Richest 69/369 (18.7) 40/233 (17.2) 11/97 (11.3)
Missed a meal
Never 272/369 (73.7) 147/232 (63.4) 60/96 (62.5)
Sometimes 68/369 (18.4) 50/232 (21.6) 24/96 (25.0)
Always or often 29/369 (7.9) 35/232 (15.1) 12/96 (12.5)
Travel time to facility
Mean (SD) 57 (53.8) 59 (54.9)
<60 229/368 (62.2) 132/232 (56.9)
>60 139/368 (37.8) 100/232 (43.1)
Time since HIV positive, years
Mean (SD) 2.5 (3.1) 3.5 (3.6)
Time on ART, months
Mean (SD) 5.4 (3.1) 7.0 (3.4)
SD, standard deviation.
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the MaxART program [21]. In our sub-study, only
21.5% of those who started ART in the intervention
group reported feeling ill at the time of ART initiation,
which shows that the majority of patients start ART
despite feeling healthy. The most cited reasons to start
ART in the intervention group are wanting to avoid
becoming sick or being explained that one can start ART
regardless of health status or CD4 count. In addition,
those that did not feel ill at ART initiation reported being
more adherent than those that did feel ill, which indicates
that feeling healthy was not a barrier to adherence for
the majority of participants in this study.
A qualitative MaxART study on healthcare providers’
perspectives of early ART revealed that health providers
were motivating clients to start ART early in order to
avoid severe illness and becoming ‘bed ridden’ [22].
Avoiding visibly apparent illness was described as partic-
ularly advantageous by providers because it meant that
clients could evade disclosing their HIV status to friends
and neighbours. Whilst we reported high levels of disclo-
sure to partners and family members, only a small per-
centage (12.1% in the control group and 16.2% in the
intervention group) reported having disclosed to someone
other than partner or family. This confirms qualitative
Table 2 Disclosure and adherence
Control Intervention (t0) Intervention (t0) Intervention (t1)
n/N (%) n/N (%) P n/N (%) n/N (%) P
N 369 (100) 233 (100) 97 (100) 97 (100)
Disclosure
Keeps HIV status a
secret from most people
237/367 (64.6) 159/232 (68.5) 0.319 71/96 (74.0) 60/96 (62.5) 0.088
HIV results shared with
anyone outside the health clinic
364/369 (98.6) 229 (98.7) 0.949 94/96 (97.9) 97/97 (100) 0.153
Shared with Partner 314/335 (93.7) 182/194 (93.8) 0.970 76/83 (91.6) 79/85 (92.9) 0.739
Shared with Family 284/364 (78.0) 180/229 (78.6) 0.867 68/96 (70.8) 75/97 (77.3) 0.428
Shared with Other 44/364 (12.1) 37/229 (16.2) 0.160 16/96 (16.7) 16/97 (16.5) 0.922
Worried that visiting HTC
services or taking ART may
disclose HIV status
34/368 (9.2) 37/229 (16.0) 0.012 19/95 (20.0) 16/96 (16.7) 0.552
Attending HIV services or
taking ART has caused
disclosure HIV status
52/365 (14.3) 46/228 (20.2) 0.059 22/92 (23.9) 20/97 (20.6) 0.586
Adherence
Dose missed in the last 30 days 54/369 (14.6) 38/232 (16.4) 0.563 12/95 (12.3) 10/96 (10.3) 0.632
Table 3 Patient experiences of testing and ART initiation
Control Intervention (t0) Intervention (t0) Intervention (t1)
n/N (%) n/N (%) P n/N (%) n/N (%) P
N 369 (100) 233 (100) 97 (100) 97 (100)
Feeling ill when testing 134/368 (36.4) 72/224 (30.9) 0.165 – –
Feeling ill when starting ART 120/369 (32.5) 50/233 (21.5) 0.003 – –
Felt pressured to start ART 38/368 (10.3) 25/233 (10.7) 0.875 – –
At ART initiation
Explain the meaning of the CD4 count
results and the viral load test
49/333 (14.7) 94/202 (46.5) <0.001 – –
Explain it was your choice to start ART 321/366 (87.7) 217/233 (93.1) 0.032 – –
Gave you time to ask questions 309/364 (84.9) 201/231 (87.0) 0.471 – –
At refill
Asks if you have any problems with
taking ART
294/369 (79.7) 185/231 (80.1) 0.903 78/96 (81.3) 69/97 (71.1) 0.099
Gives you back CD4 results and viral
load test results
45/349 (12.9) 102/225 (45.3) <0.001 38/95 (40.0) 61/97 (62.9) 0.002
Gives you time to ask questions 295/369 (80.0) 174/231 (75.3) 0.182 70/95 (73.7) 67/97 (69.1) 0.480
568 © 2019 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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insights from MaxART which revealed that disclosure
was generally reserved for one’s immediate family, and
few people reported disclosure to non-family members
[21].
With regard to healthcare interactions we found that
the communication between patient and healthcare provi-
der at the initiation of ART improved after the interven-
tion. Test results were more widely shared with the
patients after the intervention due to a wider access to
point of care CD4-cell count machines and routine viral
load monitoring. In contrast, fewer patients were asked
about problems with taking ART over time. At interven-
tion t1, clinical mentors worked on improving the logis-
tics around viral load tests and how the results were
explained to patients, which probably contributed to the
improvement in giving back test results in intervention
t1, but the increased time dedicated to giving back the
results might have led to less time for the other topics.
Another explanation might be that the healthcare work-
ers assume that problems such as side effects related to
taking ART will arise shortly after the initiation and to a
lesser extent later on, and therefore less time is spent on
inquiring about problems with ART as time passes.
This study compared the respondents before and after
intervention, but also aimed to follow-up the respondents
after the intervention, to assess if the results were sus-
tained. One of the limitations is that the data were col-
lected using face-to-face interviews, which might have
introduced a social desirability bias. Treatment adherence
was self-reported, however, literature suggest that self-
reported treatment adherence is, in general, a reliable
measure [23–27]. Using the same methodology in both
comparison groups makes that true differences should
not be affected. Linking between intervention t0 and t1
was based on personal identifying number, which was
not always recorded, resulting in the use of different
matching strategies. This might have led to false match-
ing results. With the absence of the initial study number
being due to operational issues, rather than patient char-
acteristics, we feel that this potential miss-matches do not
influence the validity of our results.
Comparing the respondents interviewed before and
during the intervention, the mean time since HIV positive
diagnosis is longer after the intervention was introduced,
which means respondents recruited in intervention groups
had more time to disclose. However, since the proportion
of people who disclosed is already high, namely 94% dis-
closed to partner in the control group, the difference in
time since HIV positive diagnosis probably did not have
much effect. We managed to follow-up 43% of respon-
dents 6 months after the first interview, which might
have introduced a selection bias. We tried to correct this
using analysis-weights based on sex, age, wealth index,
religion, marital status, education, religion and recruit-
ment facility of the respondent. However, this resulted in
unstable weights due to the limited numbers and did not
allow us to reach valid estimates. Hence, we present
unweighted estimates that might suffer from bias, if the
loss to follow-up is associated with the outcome, which
could be the case for adherence. In this case, we may
have overestimated the proportion that was adherent.
Conclusion
This study challenges the concerns that early initiation of
ART would lead to less adherence, less disclosure or
more pressure to start ART. We found that the interven-
tion improved the interaction with healthcare workers,
this might be due to training and mentoring of healthcare
workers and will be important for a successful roll-out of
immediate ART.
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